Second-Half Vascepa Sales Growth Still in Focus for Amarin (AMRN); Aegis Maintains at 'Hold'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq hits intraday record high on Alphabet boost, Mideast negotiation hopes
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
MKM Lowers Fair Value, Adjusts Estimates on Amarin (AMRN) Following Q1 Results
May 12, 2014 12:19 PM EDTMKM Partners is lowering its fair value estimate on Amarin (Nasdaq: AMRN) from $2 down to $1.50, while maintaining the stock at Neutral.
Analyst Jon LeCroy commented, Vascepa prescriptions are again growing and the Kowa co-promote, scheduled to begin this month, is... More
UPDATE: Citi Downgrades Amarin Corporation (AMRN) to Neutral
May 12, 2014 6:42 AM EDT(Updated - May 12, 2014 10:07 AM EDT)
Citi downgraded Amarin Corporation (NASDAQ: AMRN) from Buy to Neutral with a price target of $1.75. Analyst Jonathan Eckard thinks shares will trade range-bound near-term.
"We are downgrading AMRN to Neutral from Buy, finding it harder to see when Vascepa sales could turn a corner to drive support back to the stock. Dragging sales... More
Amarin Corp Plc (AMRN) Posts Q1 Loss of 16c/Share; Updates on Ops
May 9, 2014 7:03 AM EDTAmarin Corp Plc (NASDAQ: AMRN) reported Q1 EPS of ($0.16), $0.02 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $11 million versus the consensus estimate of $11.65 million.
Operational update
Commercialization and regulatory update
Amarin is now available on formulary to over 200 million lives in the United States, including over 100 million with Tier 2 coverage. As the company works to continue to increase the productivity of our sales representatives and work with our new co-promotion partner, Kowa Pharmaceuticals America, the company believes Vascepa sales will continue to... More
